Recent advances and future directions on small molecule VEGFR inhibitors in oncological conditions

Thakur, Amandeep; Rana, Mandeep; Mishra, Anshul; Kaur, Charanjit; Pan, Chun-Hsu; Nepali, Kunal

doi:10.1016/j.ejmech.2024.116472

Cited by 3 publications

(1 citation statement)

References 268 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cluster 2 was divided into four clusters, with tivozanib ( 14 ) as the medoid of the most populated subcluster (Cluster 2A, 196 molecules out of 625). Tivozanib ( 14 ) is a quinoline-derived VEGF receptor tyrosine kinase inhibitor that blocks angiogenesis in tumors [ 28 ]. In addition, 14 has an isoxazole ring in its structure.…”

Section: Resultsmentioning

confidence: 99%

Remapping the Chemical Space and the Pharmacological Space of Drugs: What Can We Expect from the Road Ahead?

Franco,

de Jesus,

Pinheiro

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

This work examines the current landscape of drug discovery and development, with a particular focus on the chemical and pharmacological spaces. It emphasizes the importance of understanding these spaces to anticipate future trends in drug discovery. The use of cheminformatics and data analysis enabled in silico exploration of these spaces, allowing a perspective of drugs, approved drugs after 2020, and clinical candidates, which were extracted from the newly released ChEMBL34 (March 2024). This perspective on chemical and pharmacological spaces enables the identification of trends and areas to be occupied, thereby creating opportunities for more effective and targeted drug discovery and development strategies in the future.

show abstract

Section: Resultsmentioning

confidence: 99%